Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:ETNB NASDAQ:FBIO NASDAQ:FBRX NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.81+0.9%$3.02$1.30▼$4.08$743.72M0.684.00 million shs607,989 shsETNB89BIO$14.79-0.1%$11.06$4.16▼$15.06$2.19B1.272.84 million shs1.47 million shsFBIOFortress Biotech$2.76-1.6%$2.88$1.33▼$4.20$81.96M1.75499,071 shs321,113 shsFBRXForte Biosciences$14.85+0.6%$12.31$4.11▼$28.68$184.52M3.0367,846 shs9,085 shsVSTMVerastem$8.88-4.5%$8.78$2.54▼$11.24$546.17M0.891.86 million shs767,196 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+1.09%-6.40%-5.76%-28.35%+110.61%ETNB89BIO0.00%-0.47%+83.40%+40.82%+89.99%FBIOFortress Biotech+3.32%-9.97%-28.02%+44.33%+71.78%FBRXForte Biosciences-3.41%+2.22%+39.68%+56.08%+224.18%VSTMVerastem+8.40%+7.90%-4.42%+89.98%+212.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.81+0.9%$3.02$1.30▼$4.08$743.72M0.684.00 million shs607,989 shsETNB89BIO$14.79-0.1%$11.06$4.16▼$15.06$2.19B1.272.84 million shs1.47 million shsFBIOFortress Biotech$2.76-1.6%$2.88$1.33▼$4.20$81.96M1.75499,071 shs321,113 shsFBRXForte Biosciences$14.85+0.6%$12.31$4.11▼$28.68$184.52M3.0367,846 shs9,085 shsVSTMVerastem$8.88-4.5%$8.78$2.54▼$11.24$546.17M0.891.86 million shs767,196 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+1.09%-6.40%-5.76%-28.35%+110.61%ETNB89BIO0.00%-0.47%+83.40%+40.82%+89.99%FBIOFortress Biotech+3.32%-9.97%-28.02%+44.33%+71.78%FBRXForte Biosciences-3.41%+2.22%+39.68%+56.08%+224.18%VSTMVerastem+8.40%+7.90%-4.42%+89.98%+212.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.71Moderate Buy$6.75140.64% UpsideETNB89BIO 2.40Hold$25.8174.59% UpsideFBIOFortress Biotech 2.33Hold$16.50498.91% UpsideFBRXForte Biosciences 2.50Moderate Buy$68.00358.07% UpsideVSTMVerastem 2.80Moderate Buy$13.2949.70% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, VSTM, FBIO, FBRX, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AKBAAkebia TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FBIOFortress BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FBRXForte BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VSTMVerastemWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025AKBAAkebia TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025FBIOFortress BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025FBRXForte BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VSTMVerastemWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/19/2025ETNB89BIORaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Market Perform(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M4.64N/AN/A($0.23) per share-12.20ETNB89BION/AN/AN/AN/A$3.34 per shareN/AFBIOFortress Biotech$57.67M1.42N/AN/A($0.06) per share-45.92FBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/AVSTMVerastem$10K54,616.75N/AN/A($0.65) per share-13.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)ETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)FBIOFortress Biotech-$46M-$1.05N/AN/AN/A-24.84%-301.81%-27.48%11/13/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)VSTMVerastem-$130.64M-$3.28N/AN/AN/AN/AN/A-119.85%11/5/2025 (Estimated)Latest AKBA, VSTM, FBIO, FBRX, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025AKBAAkebia Therapeutics-$0.02N/AN/AN/A$52.06 millionN/A11/6/2025Q3 2025ETNB89BIO-$0.50N/AN/AN/AN/AN/A11/5/2025Q3 2025VSTMVerastem-$0.71N/AN/AN/AN/AN/A8/14/2025Q2 2025FBIOFortress Biotech-$0.31-$0.46-$0.15$0.45$14.53 million$16.41 million8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/7/2025Q2 2025VSTMVerastem-$0.64-$0.39+$0.25-$0.39$6.01 million$2.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84ETNB89BIO0.0715.1915.19FBIOFortress Biotech1.341.921.70FBRXForte BiosciencesN/A11.7411.74VSTMVerastem2.063.463.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ETNB89BION/AFBIOFortress Biotech96.51%FBRXForte Biosciences77.63%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ETNB89BIO2.80%FBIOFortress Biotech27.90%FBRXForte Biosciences5.90%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.14 million257.19 millionOptionableETNB89BIO40148.31 million144.16 millionOptionableFBIOFortress Biotech17029.75 million21.45 millionOptionableFBRXForte Biosciences512.43 million11.70 millionOptionableVSTMVerastem5061.54 million60.25 millionOptionableAKBA, VSTM, FBIO, FBRX, and ETNB HeadlinesRecent News About These CompaniesVerastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average - Here's What HappenedOctober 14 at 3:34 AM | marketbeat.comVerastem's (VSTM) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comVerastem: Navigating Critical Steps In Commercialization And Development (Downgrade)October 7, 2025 | seekingalpha.comVerastem (NASDAQ:VSTM) Shares Up 4.9% - Still a Buy?October 7, 2025 | marketbeat.comVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 7, 2025 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Given Average Rating of "Moderate Buy" by BrokeragesOctober 6, 2025 | marketbeat.comVerastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average - Should You Sell?October 4, 2025 | marketbeat.comWall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"September 21, 2025 | marketbeat.comVerastem (VSTM) Upgraded to Buy: Here's What You Should KnowSeptember 19, 2025 | zacks.comVerastem (NASDAQ:VSTM) Trading Up 5.6% - Still a Buy?September 18, 2025 | marketbeat.comVerastem, Inc. $VSTM Shares Acquired by Goldman Sachs Group Inc.September 18, 2025 | marketbeat.comTop Biotech Picks for 2025: BTIG Research Highlights Potential WinnersSeptember 16, 2025 | finance.yahoo.comVerastem (NASDAQ:VSTM) Lowered to Sell Rating by Wall Street ZenSeptember 15, 2025 | marketbeat.comVerastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic OutlookSeptember 9, 2025 | tipranks.comLeerink says competitor data suggest promising view for Revolution’s zoldonrasibSeptember 8, 2025 | msn.comVerastem Updates on Cancer Therapy DevelopmentsSeptember 8, 2025 | tipranks.comVerastem Oncology to Present at Upcoming Investor ConferencesAugust 27, 2025 | mms.businesswire.comVerastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?August 25, 2025 | tipranks.comBalyasny Asset Management L.P. Increases Stake in Verastem IncAugust 20, 2025 | gurufocus.comVerastem Advances with Phase 3 Trial Progress and Product Launch Boosting ProspectsAugust 17, 2025 | insidermonkey.comVerastem Advances with Phase 3 Trial Progress and Product Launch Boosting ProspectsAugust 17, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, VSTM, FBIO, FBRX, and ETNB Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.80 +0.03 (+0.90%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.89BIO NASDAQ:ETNB$14.78 -0.02 (-0.10%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Fortress Biotech NASDAQ:FBIO$2.76 -0.05 (-1.61%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Forte Biosciences NASDAQ:FBRX$14.84 +0.10 (+0.64%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Verastem NASDAQ:VSTM$8.88 -0.42 (-4.47%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
